# Pairidex

Source: https://onco.cc/companies/pairidex/  
OnCo record `pairidex` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pairidex makes a personalised blood test that tracks the gene fusion driving a person's leukaemia, so their doctors can see how well treatment is working and spot a return of the disease early.

## Summary

Pairidex is a St. Louis company developing FusionMRD, a personalised droplet digital PCR assay that detects the gene fusion driving an individual patient's blood cancer, for monitoring treatment response and long-term surveillance of measurable residual disease. It starts with fusion-driven acute myeloid leukaemia and runs the test in a CLIA-certified, CAP-accredited laboratory. Andrew Young is founder and chief scientific officer. In February 2026 it announced a pre-seed lead investment from BioGenerator Ventures, and in July 2026 it closed an oversubscribed seed round bringing in USD 4.89 million to support the commercial launch of FusionMRD; the company described the seed investor only as a large, publicly held strategic company.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: St. Louis, MO
- Type: diagnostics
- Website: https://www.pairidex.com/

## Notes

- Founding year not stated; the St. Louis Business Journal reported in February 2026 that the company had established operations just over a year earlier. The funding source is the company's news page, which links the EIN Presswire releases. Analytical performance claims were not checked against a publication.

## Sources

- Official website: https://www.pairidex.com/
- Company news and funding releases: https://www.pairidex.com/news

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)

---
JSON: https://onco.cc/api/v1/entities/pairidex.json